The ROI for Targeted Therapies: A Strategic Perspective
September 29, 2008 Assessing the Barriers and Incentives for Adopting Personalized Medicine The Deloitte Center for Health Solutions takes an in-depth look at personalized medicine's economic value proposition and the importance of ROI for multiple stakeholders in advancing adoption of personalized medicine. Each return on investment was different according to each stakeholder: consumers, payers, diagnostic test makers, and biotechnology or pharmaceutical firms. Download the Report . . .
